Pain treatment has remained essentially unchanged for over 50 years. Peripherally acting kappa opioid receptor agonists (KORAs) offer a promising new path to the treatment of pain while minimizing the side effects associated with mu opioid receptor analgesics and other commonly used medications. Peripherally acting kappa agonists may also represent a novel, better tolerated, class of anti-inflammatory and analgesic drugs for the treatment of acute and chronic pain.1


In a double-blind, randomized, placebo-controlled, parallel-group study conducted in laparoscopic hysterectomy in 22 clinical sites in the US, patients who received a peripherally acting KORA reported a significant decrease in pain intensity and increase in pain relief. It was most efficacious when dosed both before and after surgery. A peripherally acting KORA was safe and well-tolerated when administered perioperatively, before and/or after surgery, and patients reported higher levels of satisfaction and lower levels of post-operative nausea and vomiting after being treated with a peripherally acting KORA.2

1 Menzaghi F et al. Development of the novel, peripherally-selective kappa opioid agonist cr665 for the treatment of acute pain. Cara Therapeutics Inc.
2 Medve RA et al. Analgesic efficacy of the peripheral kappa opioid agonist CR845 in laparoscopic hysterectomy. Presented at the American Academy of Pain Medicine’s 31st Annual Meeting, March 19-22, 2015, National Harbor, MD.